261 related articles for article (PubMed ID: 32238341)
1. Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.
Drain P; Ngure K; Mugo N; Spinelli M; Chatterjee P; Bacchetti P; Glidden D; Baeten J; Gandhi M
JMIR Res Protoc; 2020 Apr; 9(4):e15029. PubMed ID: 32238341
[TBL] [Abstract][Full Text] [Related]
2. A Text Messaging-Based Support Intervention to Enhance Pre-exposure Prophylaxis for HIV Prevention Adherence During Pregnancy and Breastfeeding: Protocol for a Randomized Controlled Trial.
Mogaka JN; Otieno FA; Akim E; Beima-Sofie K; Dettinger J; Gomez L; Marwa M; Odhiambo B; Ngure K; Ronen K; Sharma M; John-Stewart G; Richardson B; Stern J; Unger J; Udren J; Watoyi S; Pintye J; Kinuthia J
JMIR Res Protoc; 2023 Jan; 12():e41170. PubMed ID: 36716092
[TBL] [Abstract][Full Text] [Related]
3. Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda.
Mujugira A; Karungi B; Mugisha J; Nakyanzi A; Nampewo O; Naddunga F; Kamusiime B; Nsubuga R; Nyanzi KR; Muwonge TR; Wyatt MA; Ware NC; Gandhi M; Haberer JE
J Int AIDS Soc; 2024 May; 27(5):e26255. PubMed ID: 38695107
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
5. Adapting Effective mHealth Interventions to Improve Uptake and Adherence to HIV Pre-Exposure Prophylaxis Among Thai Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial.
Wang B; Janamnuaysook R; MacDonell K; Rongkavilit C; Schieber E; Naar S; Phanuphak N
JMIR Res Protoc; 2023 Sep; 12():e46435. PubMed ID: 37665622
[TBL] [Abstract][Full Text] [Related]
6. Optimizing an mHealth Intervention to Improve Uptake and Adherence to HIV Pre-exposure Prophylaxis in Young Transgender Women: Protocol for a Multi-Phase Trial.
MacDonell KK; Wang B; Phanuphak N; Janamnuaysook R; Srimanus P; Rongkavilit C; Naar S
JMIR Res Protoc; 2022 May; 11(5):e37659. PubMed ID: 35587370
[TBL] [Abstract][Full Text] [Related]
7. MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.
Mantell J; Franks J; Zerbe A; Lamb MR; Reed DM; Omollo D; Lahuerta M; Naitore D; El-Sadr WM; Agot K
BMJ Open; 2022 Nov; 12(11):e064037. PubMed ID: 36332953
[TBL] [Abstract][Full Text] [Related]
8. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
9. A Digital Gaming Intervention to Improve HIV Testing for Adolescents and Young Adults: Protocol for Development and a Pilot Randomized Controlled Trial.
Castel AD; Wilbourn B; Trexler C; D'Angelo LD; Greenberg D
JMIR Res Protoc; 2021 Jun; 10(6):e29792. PubMed ID: 34185022
[TBL] [Abstract][Full Text] [Related]
10. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
11. An Electronic Pre-Exposure Prophylaxis Initiation and Maintenance Home Care System for Nonurban Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial.
Siegler AJ; Brock JB; Hurt CB; Ahlschlager L; Dominguez K; Kelley CF; Jenness SM; Wilde G; Jameson SB; Bailey-Herring G; Mena LA
JMIR Res Protoc; 2019 Jun; 8(6):e13982. PubMed ID: 31199326
[TBL] [Abstract][Full Text] [Related]
12. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
13. Online-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study).
Groot Bruinderink ML; Boyd A; Coyer L; Boers S; Blitz L; Brand JM; Götz HM; Stip M; Woudstra J; Yap K; Vermey K; Matser A; Feddes AR; Jongen VW; Prins M; Hoornenborg E; van Harreveld F; Schim van der Loeff MF; Davidovich U
JMIR Res Protoc; 2023 Nov; 12():e51023. PubMed ID: 37938875
[TBL] [Abstract][Full Text] [Related]
14. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya.
Ortblad KF; Kearney JE; Mugwanya K; Irungu EM; Haberer JE; Barnabas RV; Donnell D; Mugo NR; Baeten JM; Ngure K
Trials; 2019 Jul; 20(1):396. PubMed ID: 31272495
[TBL] [Abstract][Full Text] [Related]
16. Establishing Novel Antiretroviral Imaging for Hair to Elucidate Nonadherence: Protocol for a Single-Arm Cross-sectional Study.
Poliseno A; Ferguson E; Perry R; Munson A; Davis A; Hill L; Keys J; White N; Farel C; Gay C; Golin C; Rosen E; Kashuba A
JMIR Res Protoc; 2023 Apr; 12():e41188. PubMed ID: 37083754
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations.
Spinelli MA; Rodrigues WC; Wang G; Vincent M; Glidden DV; Okochi H; Stalter R; Defechereux P; Deutsch M; Grant RM; Ngure K; Mugo NR; Baeten JM; Gandhi M;
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):149-152. PubMed ID: 32167963
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, Acceptability, and Feasibility of a Telehealth HIV Pre-Exposure Prophylaxis Care Intervention Among Young Cisgender Men and Transgender Women Who Have Sex With Men: Protocol for a Randomized Controlled Trial.
Braun RA; Erenrich RK; Coyle KK; Doan TP; Klausner JD
JMIR Res Protoc; 2023 Sep; 12():e47932. PubMed ID: 37713244
[TBL] [Abstract][Full Text] [Related]
20. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
